Ghelardi R - Search Results

1

Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide.

Lunati ME, Cimino V, Bernasconi D, Gandolfi A, Morpurgo PS, Tinari C, Lazzaroni E, Baruffaldi L, Muratori M, Montefusco L, Pastore I, Rossi A, Franzetti IG, Muratori F, Manfrini R, Disoteo OE, Terranova R, Desenzani P, Girelli A, Ghelardi R, D'Addio F, Ben Nasr M, Berra C, Folli F, Bucciarelli L, Fiorina P. Lunati ME, et al. Among authors: ghelardi r. Pharmacol Res. 2024 Jan;199:107040. doi: 10.1016/j.phrs.2023.107040. Epub 2023 Dec 20. Pharmacol Res. 2024. PMID: 38128857 Free article.

2

AWARE A novel web application to rapidly assess cardiovascular risk in type 2 diabetes mellitus.

Berra C, Manfrini R, Mirani M, Bucciarelli L, Zakaria AS, Piccini S, Ghelardi R, Lunati ME, Rodovalho S, Bifari F, Fiorina P, Folli F. Berra C, et al. Among authors: ghelardi r. Acta Diabetol. 2023 Sep;60(9):1257-1266. doi: 10.1007/s00592-023-02115-x. Epub 2023 Jun 4. Acta Diabetol. 2023. PMID: 37270748 Free PMC article.

3

Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study.

Lazzaroni E, Lunati ME, Montefusco L, Pastore I, Chebat E, Cimino V, Morpurgo PS, Muratori M, Plebani L, Bolla A, Rossi A, Vallone L, Gandolfi A, Tinari C, D'Addio F, Nasr MB, Loretelli C, Scaranna C, Bellante R, Manfrini R, Muratori F, Franzetti I, Orsi E, Gazzaruso C, Ghelardi R, Desenzani P, Genovese S, Girelli A, Folli F, Berra C, Fiorina P. Lazzaroni E, et al. Among authors: ghelardi r. Pharmacol Res. 2022 Sep;183:106374. doi: 10.1016/j.phrs.2022.106374. Epub 2022 Jul 28. Pharmacol Res. 2022. PMID: 35908663

4

Correction to: Physicians' misperceived cardiovascular risk and therapeutic inertia as determinants of low LDL-cholesterol targets achievement in diabetes.

Morieri ML, Lamacchia O, Manzato E, Giaccari A, Avogaro A; Lipid-Lowering-Relevance Study Group. Morieri ML, et al. Cardiovasc Diabetol. 2022 May 13;21(1):73. doi: 10.1186/s12933-022-01515-7. Cardiovasc Diabetol. 2022. PMID: 35562766 Free PMC article. No abstract available.

5

Physicians' misperceived cardiovascular risk and therapeutic inertia as determinants of low LDL-cholesterol targets achievement in diabetes.

Morieri ML, Lamacchia O, Manzato E, Giaccari A, Avogaro A; Lipid-Lowering-Relevance Study Group. Morieri ML, et al. Cardiovasc Diabetol. 2022 Apr 26;21(1):57. doi: 10.1186/s12933-022-01495-8. Cardiovasc Diabetol. 2022. PMID: 35473579 Free PMC article.

6

Low Ca(2+) pump activity in diabetic nephropathy.

Podestá F, Meregalli G, Ghelardi R, Del Giudice R, Asnaghi V, Maestroni A, Zerbini G. Podestá F, et al. Among authors: ghelardi r. Am J Kidney Dis. 2001 Sep;38(3):465-72. doi: 10.1053/ajkd.2001.26825. Am J Kidney Dis. 2001. PMID: 11532676

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

6 results

Search Page